{"id":"NCT02003144","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients","officialTitle":"A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-12","primaryCompletion":"2021-07-12","completion":"2021-07-12","firstPosted":"2013-12-06","resultsPosted":"2022-08-23","lastUpdate":"2022-08-23"},"enrollment":119,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neuromyelitis Optica","Neuromyelitis Optica Spectrum Disorder"],"interventions":[{"type":"BIOLOGICAL","name":"eculizumab","otherNames":["Soliris"]}],"arms":[{"label":"Eculizumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events","timeFrame":"Baseline up to end of study (up to 6.5 years)","effectByArm":[{"arm":"Placebo/Eculizumab","deltaMin":41,"sd":null},{"arm":"Eculizumab/Eculizumab","deltaMin":70,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":69,"countries":["United States","Argentina","Australia","Canada","Colombia","Croatia","Czechia","Denmark","Germany","Hong Kong","Italy","Japan","Malaysia","Russia","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["23623397","34498507","33676197"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":41},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Urinary tract infection","Arthralgia"]}}